Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy

Abstract

Purpose To assess the efficacy and safety of switching from prostaglandin analog (PGA) monotherapy to tafluprost/timolol fixed-combination (Taf/Tim) therapy. Subjects and Methods Patients with primary open-angle glaucoma, normal-tension glaucoma, or ocular hypertension who had received PGA monotherapy for at least 3 months were enrolled. Patients were examined at 1, 2, and 3 months after changing therapies. Subsequently, the patients were returned to PGA monotherapy. The examined parameters included intraocular pressure (IOP) and adverse events. A questionnaire survey was conducted after the switch to Taf/Tim therapy. Results Forty patients with a mean age of 66.5 ± 10.3 years were enrolled; 39 of these patients completed the study protocol. Switching to Taf/Tim significantly reduced the IOP from 18.2 ± 2.6 mmHg at baseline to 14.8 ± 2.5 mmHg at 1 month, 15.2 ± 2.8 mmHg at 2 months, and 14.9 ± 2.5 mmHg at 3 months (P < 0.001). Switching back to the original PGA monotherapy returned the IOP values to baseline levels. Taf/Tim reduced the pulse rate insignificantly. No significant differences were observed in blood pressure, conjunctival hyperemia, or corneal adverse events. A questionnaire showed that the introduction of Taf/Tim did not significantly influence symptoms. Conclusions Compared with PGA monotherapy, Taf/Tim fixed-combination therapy significantly reduced IOP without severe adverse events.

24-Hour Evaluation of the Effectiveness and Tolerability of Preservative-Free Tafluprost-Timolol Fixed Combination in Open-Angle Glaucoma or Ocular Hypertensive Patients Previously Treated with Preserved Latanoprost

“…This result is similar to those reported in two previous reports in which patients insufficiently controlled on prostaglandin analogue in monotherapy were switched to TTFC without a washout period. 19–23 The relative mean IOP reduction was 11.2% and 17.6%. Similarly, to our study, the patients recruited in these studies had a relatively lower baseline IOP (16.5 mmHg and 18.2 mmHg vs 17.8 mmHg, respectively).…”

Normal-Tension Glaucoma: Epidemiology, Pathogenesis, Diagnosis and Treatment. Literature Review. Part 2. Role of Vascular Dysregulation in the Pathogenesis. Treatment of Normal Tension Glaucoma

“…С другой стороны, многие авторы подчеркивают целесообразность использования фиксированных комбинаций в лечении ГНД, например описано гипотензивное действие сочетания аналогов простагландинов и бета-блокаторов при ГНД [41]. В других исследованиях было показано, что фиксированная комбинация препаратов «дорзоламид+тимолол» снижала исходное ВГД на 23,7 % у пациентов с ГНД, не получавших ранее лечение [42], а комбинированные капли «бримонидин+тимолол» снижали ВГД на 4,1 мм рт.…”